Related Experiment Video
Updated: Aug 9, 2026
06:58
Physiology Lab Demonstration: Glomerular Filtration Rate in a Rat
Published on: July 26, 2015
Disposition and response to bumetanide and furosemide
The American Journal of Cardiology
|January 24, 1986
Summary
Bumetanide is a more potent loop diuretic than furosemide, with faster absorption and higher bioavailability. Further research is needed to understand their differences in renal insufficiency and heart failure.
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- Bumetanide and furosemide are established loop diuretics.
- Understanding their comparative pharmacology is crucial for clinical application.
Purpose of the Study:
- To compare the potency, absorption, and bioavailability of bumetanide and furosemide.
- To highlight the need for further investigation into their differential effects in specific patient populations.
Main Methods:
- Comparative analysis of pharmacokinetic properties.
- Review of existing clinical data regarding elimination and absorption.
Main Results:
- Bumetanide demonstrates 40-50 times greater potency than furosemide by weight.
- Bumetanide exhibits more rapid absorption and double the bioavailability compared to furosemide.
- Both diuretics show altered elimination and absorption profiles in renal insufficiency and congestive heart failure.
Conclusions:
- Bumetanide possesses superior potency and pharmacokinetic advantages over furosemide.
- Clinical use of these diuretics may be influenced by renal function and cardiac status.
- Additional studies are required to elucidate specific clinical differences and optimize therapeutic strategies.
Related Concept Videos
01:15Drug Elimination by Renal Route: Tubular Secretion
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:25Renal Drug Excretion: Tubular Reabsorption
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...